Trial Profile
Efficacy of olmesartan medoxomil/azelnidipine combination in patients with essential hypertension
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Aug 2015
Price :
$35
*
At a glance
- Drugs Olmesartan medoxomil/azelnidipine (Primary)
- Indications Essential hypertension
- Focus Therapeutic Use
- 04 Aug 2015 New trial record
- 15 Jun 2015 Results presented at the 25th European Meeting on Hypertension and Cardiovascular Protection.